Mineralys Therapeutics Inc focuses on developing therapies for cardiovascular and cardiorenal diseases. Recent insider transactions, including significant share sales by Jon Congleton, have drawn attention. The company's stock is currently valued at $718.91 million, with various valuation metrics available for investors to consider.